Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of NGR-TNF BBB permeabilization followed by R-CHOP in relapsed/refractory primary CNS lymphoma
2014-001532-11Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NGR-TNF, rituximab, cyclophosphamide, doxorubicin, vincristine and 1 more in primary central nervous system lymphoma (PCNSL), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Feasibility of experimental treatment. Started Jul 2014; status: completed.
02
Drugs
NGR-TNFrituximabcyclophosphamidedoxorubicinvincristine
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on 2014-001532-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001532-11.